Risk identification and possible countermeasures for muscle adverse effects during statin therapy

European Journal of Internal Medicine

Volumn 26, Issue 2, 2015, Pages 82-88

  Magni, Paolo ^a,b   Macchi, Chiara ^a   Morlotti, Beatrice ^b   Sirtori, Cesare R ^a,b   Ruscica, Massimiliano ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Cardiovascular risk; Creatine kinase; Skeletal muscle toxicity; Statin related myopathy

Indexed keywords

ATORVASTATIN; CREATINE KINASE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; PITAVASTATIN; ROSUVASTATIN; SIMVASTATIN; COLESEVELAM; EZETIMIBE; HYPOCHOLESTEROLEMIC AGENT; INDOLE DERIVATIVE; MONOUNSATURATED FATTY ACID;

ARTICLE; CLINICAL FEATURE; DIET SUPPLEMENTATION; DISEASE PREDISPOSITION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MYOPATHY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT MONITORING; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; AGE; AGED; BLOOD; CHEMICALLY INDUCED; DRUG COMBINATION; DRUG INTERACTION; DYSLIPIDEMIAS; FEMALE; MALE; METABOLISM; MUSCLE DISEASE; MYALGIA; RHABDOMYOLYSIS; SEX DIFFERENCE; VERY ELDERLY; VITAMIN D DEFICIENCY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; COLESEVELAM HYDROCHLORIDE; CREATINE KINASE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; EZETIMIBE; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; MALE; MUSCULAR DISEASES; MYALGIA; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK FACTORS; ROSUVASTATIN CALCIUM; SEX FACTORS; VITAMIN D DEFICIENCY;

EID: 84924251048     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2015.01.002     Document Type: Review

References (82)

1. F.C. Taylor, M. Huffman, and S. Ebrahim Statin therapy for primary prevention of cardiovascular disease JAMA 310 2013 2451 2452
2. C.R. Sirtori The pharmacology of statins Pharmacol Res 88 2014 3 11
3. Information USFaDAFCH. FDA Expands Adiveon Statin Risks. 2014;January.
4. T.R. Joy, and R.A. Hegele Narrative review: statin-related myopathy Ann Intern Med 150 2009 858 868
5. M. Ruscica, C. Macchi, B. Morlotti, C.R. Sirtori, and P. Magni Statin therapy and related risk of new-onset type 2 diabetes mellitus Eur J Intern Med 25 2014 401 406
6. J.M. McKenney, M.H. Davidson, T.A. Jacobson, and J.R. Guyton Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force Am J Cardiol 97 2006 89C 94C
7. C.H. Rojas-Fernandez, L.B. Goldstein, A.I. Levey, B.A. Taylor, and V. Bittner An assessment by the Statin Cognitive Safety Task Force: 2014 update J Clin Lipidol 8 2014 S5 S16
8. R. Valiyil, and L. Christopher-Stine Drug-related myopathies of which the clinician should be aware Curr Rheumatol Rep 12 2010 213 220
9. P.P. Toth, C.R. Harper, and T.A. Jacobson Clinical characterization and molecular mechanisms of statin myopathy Expert Rev Cardiovasc Ther 6 2008 955 969
10. A. Draeger, K. Monastyrskaya, M. Mohaupt, H. Hoppeler, H. Savolainen, and C. Allemann Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia J Pathol 210 2006 94 102
11. P.S. Phillips, and R.H. Haas Statin myopathy as a metabolic muscle disease Expert Rev Cardiovasc Ther 6 2008 971 978
12. C. Vaklavas, Y.S. Chatzizisis, A. Ziakas, C. Zamboulis, and G.D. Giannoglou Molecular basis of statin-associated myopathy Atherosclerosis 202 2009 18 28
13. S. Pierno, M.P. Didonna, V. Cippone, A. De Luca, M. Pisoni, and A. Frigeri Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study Br J Pharmacol 149 2006 909 919
14. J. Hanai, P. Cao, P. Tanksale, S. Imamura, E. Koshimizu, and J. Zhao The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity J Clin Invest 117 2007 3940 3951
15. C.L. Corpier, P.H. Jones, W.N. Suki, E.D. Lederer, M.A. Quinones, and S.W. Schmidt Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients JAMA 260 1988 239 241
16. R.C. Pasternak, S.C. Smith Jr., C.N. Bairey-Merz, S.M. Grundy, J.I. Cleeman, and C. Lenfant ACC/AHA/NHLBI clinical advisory on the use and safety of statins Circulation 106 2002 1024 1028
17. M.J. Wilkinson, L.J. Laffin, and M.H. Davidson Overcoming toxicity and side-effects of lipid-lowering therapies Best Pract Res Clin Endocrinol Metab 28 2014 439 452
18. G.D. Norata, G. Tibolla, and A.L. Catapano Statins and skeletal muscles toxicity: from clinical trials to everyday practice Pharmacol Res 88 2014 107 113
19. D. Maji, S. Shaikh, D. Solanki, and K. Gaurav Safety of statins Indian J Endocrinol Metab 17 2013 636 646
20. J.A. Staffa, J. Chang, and L. Green Cerivastatin and reports of fatal rhabdomyolysis N Engl J Med 346 2002 539 540
21. R.S. Rosenson, S.K. Baker, T.A. Jacobson, S.L. Kopecky, and B.A. Parker An assessment by the Statin Muscle Safety Task Force: 2014 update J Clin Lipidol 8 2014 S58 S71
22. J. Armitage The safety of statins in clinical practice Lancet 370 2007 1781 1790
23. E. Bruckert, G. Hayem, S. Dejager, C. Yau, and B. Begaud Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study Cardiovasc Drugs Ther 19 2005 403 414
24. H.B. Brewer Jr. Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams Am J Cardiol 92 2003 23K 29K
25. K.E. Hansen, J.P. Hildebrand, E.E. Ferguson, and J.H. Stein Outcomes in 45 patients with statin-associated myopathy Arch Intern Med 165 2005 2671 2676
26. N.J. Stone, J.G. Robinson, A.H. Lichtenstein, C.N. Bairey Merz, C.B. Blum, and R.H. Eckel 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 63 2014 2889 2934
27. C. Cholesterol Treatment Trialists, C. Baigent, L. Blackwell, J. Emberson, L.E. Holland, and C. Reith Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
28. I. Szadkowska, A. Stanczyk, W.S. Aronow, J. Kowalski, L. Pawlicki, and A. Ahmed Statin therapy in the elderly: a review Arch Gerontol Geriatr 50 2010 114 118
29. N.J. Stone, J.G. Robinson, A.H. Lichtenstein, C.N. Bairey Merz, C.B. Blum, and R.H. Eckel 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 129 2014 S1 S45
30. A.L. Catapano, Z. Reiner, G. De Backer, I. Graham, M.R. Taskinen, and O. Wiklund ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Atherosclerosis 217 2011 3 46
31. M. Natsuaki, T. Morimoto, Y. Furukawa, H. Shiomi, K. Ono, and T. Kimura Effect of statin therapy on cardiovascular outcomes after coronary revascularization in patients >/= 80 years of age: observations from the CREDO-Kyoto Registry Cohort-2 Atherosclerosis 237 2014 821 828
32. G. Savarese, A.M. Gotto Jr., S. Paolillo, C. D'Amore, T. Losco, and F. Musella Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis J Am Coll Cardiol 62 2013 2090 2099
33. T.E. Strandberg, L. Kolehmainen, and A. Vuorio Evaluation and treatment of older patients with hypercholesterolemia: a clinical review JAMA 312 2014 1136 1144
34. P. Expert Dyslipidemia, and S.M. Grundy An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia J Clin Lipidol 7 2013 561 565
35. L.S. Rallidis, K. Fountoulaki, and M. Anastasiou-Nana Managing the underestimated risk of statin-associated myopathy Int J Cardiol 159 2012 169 176
36. K.A. Kellick, M. Bottorff, and P.P. Toth A clinician's guide to statin drug-drug interactions J Clin Lipidol 8 2014 S30 S46
37. R. McPherson, J. Frohlich, G. Fodor, J. Genest, and Canadian Cardiovascular S Canadian Cardiovascular Society position statement - recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease Can J Cardiol 22 2006 913 927
38. C.H. Chang, M. Kusama, S. Ono, Y. Sugiyama, T. Orii, and M. Akazawa Assessment of statin-associated muscle toxicity in Japan: a cohort study conducted using claims database and laboratory information BMJ Open 3 2013
39. M. Needham, and F.L. Mastaglia Statin myotoxicity: a review of genetic susceptibility factors Neuromuscul Disord 24 2014 4 15
40. C.R. Sirtori, G. Mombelli, M. Triolo, and R. Laaksonen Clinical response to statins: mechanism(s) of variable activity and adverse effects Ann Med 44 2012 419 432
41. W.J. Canestaro, M.A. Austin, and K.E. Thummel Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review Genet Med 16 2014 810 819
42. A.L. Catapano Statin-induced myotoxicity: pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular reference to pitavastatin Curr Vasc Pharmacol 10 2012 257 267
43. C.G. Rowan, S.M. Brunelli, J. Munson, J. Flory, P.P. Reese, and S. Hennessy Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network Pharmacoepidemiol Drug Saf 21 2012 494 506
44. R. Laaksonen On the mechanisms of statin-induced myopathy Clin Pharmacol Ther 79 2006 529 531
45. M. Hermann, M.P. Bogsrud, E. Molden, A. Asberg, B.U. Mohebi, and L. Ose Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy Clin Pharmacol Ther 79 2006 532 539
46. S. Bellosta, R. Paoletti, and A. Corsini Safety of statins: focus on clinical pharmacokinetics and drug interactions Circulation 109 2004 III50 III57
47. P.J. Neuvonen, M. Niemi, and J.T. Backman Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance Clin Pharmacol Ther 80 2006 565 581
48. A.L. Catapano Pitavastatin - pharmacological profile from early phase studies Atherosclerosis Suppl 11 2010 3 7
49. M.H. Davidson, and J.G. Robinson Safety of aggressive lipid management J Am Coll Cardiol 49 2007 1753 1762
50. A. Kashani, C.O. Phillips, J.M. Foody, Y. Wang, S. Mangalmurti, and D.T. Ko Risks associated with statin therapy: a systematic overview of randomized clinical trials Circulation 114 2006 2788 2797
51. G. Fernandez, E.S. Spatz, C. Jablecki, and P.S. Phillips Statin myopathy: a common dilemma not reflected in clinical trials Cleve Clin J Med 78 2011 393 403
52. H.V. Ganga, H.B. Slim, and P.D. Thompson A systematic review of statin-induced muscle problems in clinical trials Am Heart J 168 2014 6 15
53. FDA FDA Drug Safety Communication: new restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury http://www.fda.gov/Drugs/DrugSafety/ucm256581.htm 2011 (editor)
54. J. Armitage, L. Bowman, K. Wallendszus, R. Bulbulia, K. Rahimi, and R. Haynes Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial Lancet 376 2010 1658 1669
55. C. Newman, J. Tsai, M. Szarek, D. Luo, and E. Gibson Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients Am J Cardiol 97 2006 61 67
56. K.D. Ballard, and P.D. Thompson Does reduced creatine synthesis protect against statin myopathy? Cell Metab 18 2013 773 774
57. J.A. Farmer The effect of statins on skeletal muscle function: the STOMP trial Curr Atheroscler Rep 15 2013 347
58. R. Laaksonen STOMPing forward: statins, muscle complaints and CK Atherosclerosis 230 2013 256 257
59. T. Teramoto Pitavastatin: clinical effects from the LIVES Study Atherosclerosis Suppl 12 2011 285 288
60. C.A. Sponseller, R.E. Morgan, V.A. Kryzhanovski, S.E. Campbell, and M.H. Davidson Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial Clin Ther 36 2014 1211 1222
61. J. Hsia, J.G. MacFadyen, J. Monyak, and P.M. Ridker Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol < 50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) J Am Coll Cardiol 57 2011 1666 1675
62. P.D. Thompson, P.M. Clarkson, and R.S. Rosenson An assessment of statin safety by muscle experts Am J Cardiol 97 2006 69C 76C
63. R.H. Eckel Approach to the patient who is intolerant of statin therapy J Clin Endocrinol Metab 95 2010 2015 2022
64. A.L. Catapano, G.D. Norata, and A. Pirillo Therapy and clinical trials: aggressive statin therapy versus combined and emerging approaches Curr Opin Lipidol 22 2011 324 325
65. S. Sathasivam Statin induced myotoxicity Eur J Intern Med 23 2012 317 324
66. K. Mergenhagen, M. Ott, K. Heckman, L.M. Rubin, and K. Kellick Low vitamin D as a risk factor for the development of myalgia in patients taking high-dose simvastatin: a retrospective review Clin Ther 36 2014 770 777
67. J. Hippisley-Cox, and C. Coupland Individualising the risks of statins in men and women in England and Wales: population-based cohort study Heart 96 2010 939 947
68. G.B. Mancini, S. Baker, J. Bergeron, D. Fitchett, J. Frohlich, and J. Genest Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference Can J Cardiol 27 2011 635 662
69. B.A. Parker, A.L. Augeri, J.A. Capizzi, K.D. Ballard, C. Troyanos, and A.L. Baggish Effect of statins on creatine kinase levels before and after a marathon run Am J Cardiol 109 2012 282 287
70. M. Needham, V. Fabian, W. Knezevic, P. Panegyres, P. Zilko, and F.L. Mastaglia Progressive myopathy with up-regulation of MHC-I associated with statin therapy Neuromuscul Disord 17 2007 194 200
71. P. Grable-Esposito, H.D. Katzberg, S.A. Greenberg, J. Srinivasan, J. Katz, and A.A. Amato Immune-mediated necrotizing myopathy associated with statins Muscle Nerve 41 2010 185 190
72. P. Mohassel, and A.L. Mammen Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies Muscle Nerve 48 2013 477 483
73. A.J. Keating, K.B. Campbell, and J.R. Guyton Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy Ann Pharmacother 47 2013 398 404
74. M.A. Cornier, and R.H. Eckel Non-traditional dosing of statins in statin-intolerant patients - is it worth a try? Curr Atheroscler Rep 17 2015 475
75. M. Arca, and G. Pigna Treating statin-intolerant patients Diabetes Metab Syndr Obes 4 2011 155 166
76. A.S. Wierzbicki, A. Viljoen, T.C. Hardman, and D.P. Mikhailidis New therapies to reduce low-density lipoprotein cholesterol Curr Opin Cardiol 28 2013 452 457
77. M. Florentin, E.N. Liberopoulos, C.V. Rizos, A.A. Kei, G. Liamis, and M.S. Kostapanos Colesevelam plus rosuvastatin 5 mg/day versus rosuvastatin 10 mg/day alone on markers of insulin resistance in patients with hypercholesterolemia and impaired fasting glucose Metab Syndr Relat Disord 11 2013 152 156
78. E.A. Stein, C.M. Ballantyne, E. Windler, P.A. Sirnes, A. Sussekov, and Z. Yigit Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins Am J Cardiol 101 2008 490 496
79. J.M. Backes, C.A. Gibson, J.F. Ruisinger, and P.M. Moriarty The high-dose rosuvastatin once weekly study (the HD-ROWS) J Clin Lipidol 6 2012 362 367
80. M. Ruscica, M. Gomaraschi, G. Mombelli, C. M., R. Bosisio, and F. Pazzucconi Nutraceutical approach to moderate cardiometabolic risk: results of a randomized, double-blind and crossover study with Armolipid Plus 2014 8
81. D.J. Becker, R.Y. Gordon, S.C. Halbert, B. French, P.B. Morris, and D.J. Rader Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial Ann Intern Med 150 2009 830 839
82. S.C. Halbert, B. French, R.Y. Gordon, J.T. Farrar, K. Schmitz, and P.B. Morris Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance Am J Cardiol 105 2010 198 204